GlassScriptPhysician profile
Saadia Yunus
NPI 1790808657
$2,408.93
in general payments reported to CMS, 2019-2025
31 companies · $239 in 2025
The $239 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $61.29 · 2020: $106 · 2021: $245 · 2022: $306 · 2023: $897 · 2024: $556 · 2025: $239.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,675 · Education: $16.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,674.57 |
| Education | $16.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $250.55 | 2021-2025 | |
| Genentech USA, INC. | $244.38 | 2019-2024 | Kadcyla, Perjeta, Phesgo |
| Takeda Pharmaceuticals U.S.A., INC. | $169.62 | 2022-2024 | Ninlaro, Iclusig |
| Gilead Sciences, INC. | $161.52 | 2022-2025 | Trodelvy |
| Celgene Corporation | $149.75 | 2023-2025 | Reblozyl, Pomalyst |
| Daiichi Sankyo INC. | $134.15 | 2022-2024 | Enhertu |
| Abbvie INC. | $133.52 | 2023-2025 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $121.91 | 2022-2024 | Opdivo, Opdualag |
| Cti Biopharma Corp. | $104.52 | 2023 | Vonjo |
| Janssen Biotech, INC. | $99.57 | 2020-2024 | Imbruvica |
| Regeneron Healthcare Solutions, INC. | $81.50 | 2023-2024 | Libtayo |
| Jazz Pharmaceuticals INC. | $78.55 | 2023 | Zepzelca |
| Glaxosmithkline, LLC. | $63.62 | 2023-2024 | Jemperli, Zejula |
| Pfizer INC. | $63.19 | 2022-2025 | |
| Seagen INC. | $61.85 | 2019-2023 | Adcetris |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $47.80 | 2022-2023 | Lumakras |
| Eisai INC. | $46.83 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $45.46 | 2022-2023 | Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $45.02 | 2022 | |
| G1 Therapeutics, INC. | $44.97 | 2022-2023 | Cosela |
| Agios Pharmaceuticals, INC. | $41.19 | 2024 | Pyrukynd |
| Emd Serono, INC. | $31.81 | 2021 | |
| Tempus Ai, INC | $29.54 | 2024 | |
| Eusa Pharma (US) LLC | $28.86 | 2020 | |
| Dova Pharmaceuticals | $23.92 | 2020 | |
| Deciphera Pharmaceuticals INC. | $23.22 | 2023 | Qinlock |
| Astellas Pharma US INC | $22.65 | 2023 | Padcev |
| Lilly USA, LLC | $21.79 | 2024 | Verzenio |
| Acceleron Pharma, INC. | $21.73 | 2021 | |
| Blueprint Medicines Corporation | $15.94 | 2023 | Ayvakit |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Saadia Yunus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.